Literature DB >> 10588978

The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability.

A Brindley1.   

Abstract

The phase out of chlorofluorocarbon (CFC) propellants has necessitated the reformulation of pressurized metered dose inhalers (pMDIs) with hydrofluoroalkane (HFA) propellants. One of the main challenges has been that conventional surfactants used for CFC-based pMDIs were not soluble in HFAs. Since one of the main aims of a pMDI is to deliver a reproducible dose of medication to the patient, it is vital that, for suspension-type pMDI formulations, the suspension is stabilized sufficiently for a reproducible dose to be delivered. A new technique has been developed that measures suspension stability more objectively than before. This technique, optical suspension characterization, was used to compare the performance of different formulations of respiratory drugs in HFAs. The optical suspension characterization data were correlated with conventional analytic techniques for the determination of the stability of the suspension formulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588978     DOI: 10.1016/s0091-6749(99)70034-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

1.  In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers.

Authors:  Daniela Traini; Paul M Young; Philippe Rogueda; Robert Price
Journal:  Pharm Res       Date:  2006-11-14       Impact factor: 4.200

2.  Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.

Authors:  Susan Hoe; Paul M Young; Philippe Rogueda; Daniela Traini
Journal:  AAPS PharmSciTech       Date:  2008-05-06       Impact factor: 3.246

3.  Influence of suspension stabilisers on the delivery of protein-loaded porous poly (DL-lactide-co-glycolide) (PLGA) microparticles via pressurised metered dose inhaler (pMDI).

Authors:  Elizabeth Cocks; Satyanarayana Somavarapu; Oya Alpar; David Greenleaf
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.